Argireline
A topical synthetic hexapeptide that softens dynamic expression lines by partially inhibiting the SNARE complex in facial muscles.
Argireline (Acetyl Hexapeptide-3/-8) is a synthetic hexapeptide applied topically in cosmetic formulations to reduce the appearance of expression lines. Its sequence mimics the N-terminal fragment of SNAP-25, letting it competitively interfere with SNARE complex assembly and attenuate acetylcholine-driven muscle contraction without a complete neurotoxin-class blockade. It is the most widely studied and commercially established topical anti-wrinkle peptide, with controlled human trials showing significant reductions in wrinkle depth. It is classified as a cosmetic ingredient rather than a drug and has not been evaluated by the FDA for efficacy.
Class
Synthetic hexapeptide (cosmetic ingredient)
Half-life
Short; topical application with no meaningful systemic absorption at cosmetic doses
Routes
Topical
Category
Skin, Hair & Cosmetic
Researched benefits
What it's studied for
Dynamic wrinkle reduction
Repeated topical application softens dynamic expression lines on the forehead, glabellar region and periorbital area (crow's feet). Controlled human trials document wrinkle-depth reductions of roughly 17-48% at 5-10% concentration over 4-8 weeks of twice-daily use.
Partial SNARE / SNAP-25 inhibition
By competing with endogenous SNAP-25 for binding, Argireline partially inhibits SNARE complex formation and reduces local acetylcholine release, attenuating the muscle contractions that drive dynamic wrinkle formation without eliminating muscle movement.
Non-injectable 'topical Botox' analog
It targets the same SNAP-25 pathway as botulinum toxin but as a competitive, reversible topical peptide, avoiding injection and systemic toxin risk.
Improved skin surface parameters
Randomized data show significant improvements in skin microtopography (cR2, cR3 roughness parameters) and reduced transepidermal water loss, indicating smoother surface texture alongside line softening.
Favorable tolerability
Argireline is well tolerated in the cosmetic literature, with adverse effects generally limited to mild, transient erythema at higher concentrations and no reported systemic events at topical cosmetic doses.
Mechanism
How it works
Argireline is a synthetic hexapeptide (Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2) whose sequence mimics the N-terminal fragment of SNAP-25, a core component of the SNARE protein complex at the neuromuscular junction. The SNARE complex (SNAP-25 + Syntaxin-1 + VAMP) is required for synaptic vesicle fusion and the release of acetylcholine from motor neurons onto facial muscles.
By competing with endogenous SNAP-25 for incorporation into the SNARE complex, Argireline partially destabilizes complex assembly and reduces local acetylcholine secretion. The result is a weaker muscle contraction and softening of the dynamic expression lines that repeated contraction produces. Because the inhibition is competitive and reversible rather than a complete neurotoxin-class blockade, the effect is described as softening line depth rather than fully freezing muscle movement.
In published cosmetic studies Argireline is used at 5-10% in topical formulations applied to areas of dynamic expression such as the forehead and periorbital regions. Measurable results develop over roughly 4-8 weeks of twice-daily application. Its close analog SNAP-8 (acetyl octapeptide-3) extends competitive inhibition further along the SNAP-25 docking sequence, but Argireline carries the stronger base of independent, peer-reviewed human trial data.
Dosing protocols
Dosing & administration
Dosing reflects protocols reported in research and community literature for educational purposes. It is not medical advice or a recommendation. Most peptides here are not approved for human use.
Standard cosmetic
- Dose
- 5-10% concentration in a topical formulation
- Frequency
- Twice daily
- Timing
- Applied to areas of dynamic expression (forehead, glabella, periorbital/crow's feet)
- Duration
- 4-8 weeks for visible effect; continued use to maintain
- Route
- Topical
Concentrations and application areas used in published controlled human trials; effect develops gradually over weeks.
Research compounding
- Dose
- High-purity raw powder (>=99% HPLC) weighed into a custom cosmetic base to reach 5-10%
- Frequency
- Twice daily once formulated
- Timing
- Topical, on expression-line areas
- Duration
- Ongoing per formulation protocol
- Route
- Topical
Used in cosmetic compounding research; raw powder is dissolved/dispersed into a serum or cream base. Not for injection use.
- Argireline is a topical cosmetic peptide, not a systemically dosed or injectable compound; no mcg/kg systemic dose applies.
- Effects are gradual and depend on consistent twice-daily application over 4-8 weeks.
- Often formulated alongside complementary actives (e.g. GHK-Cu or SNAP-8) for combined structural and neuromuscular effects.
- Not intended for injection under any circumstances.
Evidence
Research & clinical studies (3)
The anti-wrinkle efficacy of argireline, a synthetic hexapeptide, in Chinese subjects: a randomized, placebo-controlled study
In a 4-week double-blind RCT of 60 subjects, twice-daily topical argireline achieved 48.9% overall anti-wrinkle efficacy versus 0% for placebo, with significant reductions across objective roughness parameters.
PMID 23417317The efficacy study of the combination of tripeptide-10-citrulline and acetyl hexapeptide-3: a prospective, randomized controlled study
A 60-day RCT of 24 subjects confirmed the antiwrinkle activity of acetyl hexapeptide-3, showing significant improvements in skin microtopography (cR2, cR3) and reduced transepidermal water loss, with additive benefit from tripeptide-10-citrulline.
PMID 28150423DES-mediated self-assembled polypeptides: Synergistic neuromuscular signaling inhibition for anti-aging
A transdermal delivery system combining argireline, DDB peptide and mu-conotoxin in self-assembled nanoparticles significantly inhibited neuromuscular signaling and acetylcholine secretion and improved skin elasticity and wrinkle parameters in vitro, in vivo and in exploratory clinical assessment.
PMID 42202650Combinations
Stacking & blends
GHK-Cu + Argireline: Skin Rejuvenation & Line Reduction
Anti-aging skin rejuvenation combining structural remodeling with dynamic-line softening
GHK-Cu is a copper-binding tripeptide associated with collagen and elastin synthesis, antioxidant gene activation and tissue remodeling, while Argireline reduces neurotransmitter-mediated facial muscle contraction. Together they address skin aging through complementary structural and neuromuscular pathways.
Argireline + SNAP-8
Enhanced SNARE-targeting anti-wrinkle effect
SNAP-8 (acetyl octapeptide-3) extends competitive SNARE inhibition further along the SNAP-25 docking sequence; combining it with Argireline is used in SNARE-targeting anti-wrinkle formulations for potential additive line softening.
Safety
Side effects & considerations
Commonly reported effects
Contraindications & cautions
- None established for topical cosmetic use
No systemic adverse events have been reported at topical cosmetic doses. Argireline is not intended for injection. Individual response varies; review considerations and consult a qualified professional before use.
FAQ
Argireline — common questions
What is Argireline?
Argireline (Acetyl Hexapeptide-3/-8) is a synthetic hexapeptide applied topically in cosmetic formulations to reduce the appearance of expression lines. It partially inhibits the SNAP-25 component of the SNARE complex, weakening the muscle contractions that drive dynamic wrinkle formation.
How does Argireline work?
Its sequence mimics the N-terminal fragment of SNAP-25 and competes with the endogenous protein for SNARE complex assembly, reducing local acetylcholine release. This produces weaker muscle contraction and softening of dynamic expression lines without a complete neurotoxin-class blockade.
How is Argireline used and at what concentration?
In published studies it is used at 5-10% concentration in a topical formulation applied twice daily to areas of dynamic expression such as the forehead and around the eyes. Results typically develop over 4-8 weeks of consistent use.
How effective is Argireline?
Controlled human trials report meaningful reductions in wrinkle depth, ranging from roughly 17% to 48% depending on the study and concentration. In one 4-week RCT of 60 subjects, twice-daily argireline achieved 48.9% anti-wrinkle efficacy versus 0% for placebo.
How does Argireline compare to SNAP-8?
SNAP-8 (acetyl octapeptide-3) is a longer octapeptide analog designed to extend SNARE inhibition further along the docking sequence. Argireline has the stronger base of independent, peer-reviewed human trial data, while much SNAP-8 evidence is manufacturer-sponsored. Both are topical cosmetic ingredients without drug approval.
Is Argireline safe?
It is considered low risk and well tolerated in cosmetic use, with side effects generally limited to mild, transient redness at higher concentrations and no reported systemic events at topical doses. It should not be injected.
Is Argireline FDA-approved?
No. Argireline is sold as a cosmetic ingredient and has not been evaluated by the FDA as a drug. It has no NDA or IND and is marketed only as a cosmetic anti-wrinkle ingredient.
What is Argireline commonly stacked with?
It is frequently paired with GHK-Cu for combined structural (collagen/elastin) and neuromuscular (line-softening) effects, and with SNAP-8 in SNARE-targeting anti-wrinkle formulations.
